⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer

Official Title: Phase II Randomized Study of Soy Isoflavones in Patients With Localized Prostate Cancer Treated With Radiation Therapy

Study ID: NCT00243048

Conditions

Prostate Cancer

Study Description

Brief Summary: RATIONALE: Eating a diet high in soy foods may slow the progression of some types of cancer. Isoflavones are compounds found in soy food that may slow the growth of prostate cancer cells and prevent further development of prostate cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving isoflavones together with radiation therapy may be an effective treatment for prostate cancer. PURPOSE: This randomized phase II trial is studying the side effects and how well giving isoflavones together with radiation therapy works in treating patients with localized prostate cancer.

Detailed Description: OBJECTIVES: * Determine the effect of soy protein isolate (isoflavones) and radiotherapy on the modulation of biomarkers in patients with localized prostate cancer. * Determine the toxicity of this regimen in these patients. * Determine the effect of this regimen on the quality of life of these patients. OUTLINE: This is a randomized, placebo-controlled study. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral soy protein isolate (isoflavones) twice daily for 6 months in the absence of disease progression or unacceptable toxicity. * Arm II: Patients receive an oral placebo twice daily for 6 months in the absence of disease progression or unacceptable toxicity. In both arms, patients also undergo radiotherapy while receiving isoflavones or placebo. Quality of life is assessed periodically. PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Contact Details

Name: Omer Kucuk, MD

Affiliation: Barbara Ann Karmanos Cancer Institute

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: